EQT Exits Vivasure Medical with €100 Million Sale to Haemonetics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Newsfilter
- Strategic Exit: EQT Life Sciences successfully exits its portfolio company Vivasure Medical through a €100 million cash sale to Haemonetics, marking a significant return on investment in the medical technology sector.
- Technological Innovation: Vivasure's PerQseal® Elite system utilizes a bioabsorbable patch to provide a sutureless vascular closure solution, which is expected to enhance Haemonetics' competitiveness in the rapidly growing structural heart and endovascular surgery markets.
- Market Expansion: The acquisition includes an upfront cash payment of €100 million and up to an additional €85 million in contingent consideration based on sales growth and milestone achievements, reflecting confidence in Vivasure's future market potential.
- Investment Support: Since 2016, EQT's support for Vivasure has encompassed clinical development and market approval, underscoring the critical role of venture capital in driving medical innovation and improving patient care quality.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 78.86 USD with a low forecast of 64.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 84.040
Low
64.00
Averages
78.86
High
90.00
Current: 84.040
Low
64.00
Averages
78.86
High
90.00
About HAE
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
